15

Tabellenverzeichnis

Table 1Beteiligte Fachgesellschaften und OrganisationenOpen tableTable 2Overview of absolute data on benefits and harms of PSA-assisted screening according to Schröder et al. 2014Open tableTable 3Overview of risks identified in Lilja et al. 2011 and control intervals suggested by the authors of the studyOpen tableTable 4Detection rate ratio (Drost et al. 2019)Open tableTable 5Diagnostic precision in the detection of metastases (primary endpoint).Open tableTable 6Weight of concomitant diseases contributing to the Charlson score (Charlson et al. 1987). The Charlson score is calculated by totaling a patient's scoresOpen tableTable 7American Society of Anesthesiologists (ASA) health status classification (American Society of Anesthesiologists 2013)Open tableTable 8Studies of prostate cancer under Active Surveillance with at least 5 years of median follow-up and at least 90 patients.Open tableTable 9Morbidity and mortality after radical prostatectomyOpen tableTable 10Results of the three large RCTs on hypofractionationOpen tableTable 11LDR brachytherapy in noncomparative cohort studiesOpen tableTable 12Cohort studies comparing LDR brachytherapyOpen tableTable 13Oncological endpoints of large cohort studies (n > 300) on HIFU in localized prostate cancerOpen tableTable 14Results (follow-up > 7 years) of collectives with cT3-cT4 treated with RPEOpen tableTable 15TNM classification (7th edition) for stages T3 and T4 (source: www.cancerstaging.org)Open tableTable 16Results from the RCT TITAN on combination therapy with apalutamide, median observation time 22.7 months [Chi et al. 2019; Agarwal et al. 2019]Open tableTable 17Results from the ARCHES RCTs on combination therapy with enzalutamide (median observation time 14.4 months) [Armstrong et al. 2019]Open tableTable 18Results of RCT on combination therapy with abiraterone [Fizazi et al. 2017/2019; James et al. 2017]Open tableTable 19Results of the RCT on combined hormone chemotherapyOpen tableTable 20Typical and common side effects of hormone ablative therapy and possibilities of prophylaxis and treatment to be communicated to the patient (based on Heidenreich 2007)Open tableTable 21Prophylaxis and treatment of common side effects of chemotherapy in prostate cancerOpen tableTable 22WHO pain management schemeOpen tableTable 23Key questions and author groupsOpen tableTable 24Changes in the recommendations after update 6 of 2021Open tableTable 25Comparative overview of the side effect profile of prostate carcinoma treatmentsOpen table